Revolutionary War at Ft. Ward

Revolutionary War at Ft. Ward

drum, drumming, drummers

Drummers play “Yankee Doodle” for a crowd at the Revolutionary War Reenactment at Fort Ward Museum and Historic Site on February 20, 2011.

On Sunday I went to a Revolutionary War reenactment at Fort Ward. It was like the Civil War reenactment I attended a few weeks ago, but set about 100 years earlier. Though, it didn’t seem like the weapons and medical techniques were all that different.

pam bronson, debbie barlow, katy hayes, helen anderson, revolutionary war

From left to right, Pam Bronson, Debbie Barlow, Katy Hayes and Helen Anderson take a break from answering visitor questions during the skirmish at the Revolutionary Way Reenactment at Fort Ward Museum and Historic Site.

Kampung inhabitants need more medical personnel

Kampung inhabitants need more medical personnel

JUBI, 22 February 2011

Kampung inhabitants need more medical personnel

People living in Mosso kampung, district of Muaratami have urged the
Health Service to increase the number of medical personnel available to kampung dwellers because it is very inadequate at present.

‘We need help from the medical service because we are getting complaints every day from patients about the lack of medical facilities,’ said Charle Wetapoa, an official.

Ampio Pharmaceuticals, Inc. Announces Initiation Of Phase 1B Clinical Trial For Its Anti-inflammatory Drug Ampion™

Main Category: Arthritis / Rheumatology
Also Included In: Bones / Orthopedics;  Clinical Trials / Drug Trials;  Pharma Industry / Biotech Industry
Article Date: 01 Jun 2011 – 0:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  
<!– rate icon rate article




Patient / Public:not yet rated

Healthcare Prof:not yet rated

Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE)(“Ampio”) announced that it received ethics board approval for a Phase 1B clinical trial in Australia of its biologic anti-inflammatory agent, Ampion™. Patients are now being recruited for first dosing in the three arm, placebo controlled, 60 patient trial designed to demonstrate efficacy in the treatment of osteoarthritis of the knee as well as to confirm patient safety and tolerance.

CrystalGenomics Initiates CG100649 Phase 2b Study In Patients With Osteoarthritis

Main Category: Bones / Orthopedics
Also Included In: Arthritis / Rheumatology;  Clinical Trials / Drug Trials;  Pharma Industry / Biotech Industry
Article Date: 01 Jun 2011 – 0:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  
<!– rate icon rate article




Patient / Public:not yet rated

Healthcare Prof:not yet rated

CrystalGenomics, Inc. (Seoul, Korea) and CG Pharmaceuticals, Inc. (Emeryville, California), a biopharmaceutical company with 3 clinical stage candidates, has announced that the first patient has been enrolled for a Phase 2b clinical study of CG100649, CrystalGenomics’ clinical stage novel NSAID candidate, in patients with knee or hip osteoarthritis (OA).